Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Declines By 38.7%

by · The Markets Daily

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totaling 16,698 shares, a drop of 38.7% from the June 15th total of 27,250 shares. Based on an average daily volume of 39,560 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.0% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Rodman & Renshaw began coverage on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 target price for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $34.67.

View Our Latest Analysis on Bolt Biotherapeutics

Institutional Trading of Bolt Biotherapeutics

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its position in shares of Bolt Biotherapeutics by 40.3% during the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after acquiring an additional 22,200 shares during the period. T3 Companies LLC acquired a new stake in Bolt Biotherapeutics in the fourth quarter worth $208,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Bolt Biotherapeutics in the fourth quarter valued at $112,000. Susquehanna International Group LLP bought a new stake in Bolt Biotherapeutics in the third quarter valued at $89,000. Finally, Shay Capital LLC bought a new stake in Bolt Biotherapeutics in the third quarter valued at $85,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Trading Up 4.0%

NASDAQ BOLT opened at $4.21 on Thursday. The business has a 50 day simple moving average of $4.48 and a 200 day simple moving average of $4.89. Bolt Biotherapeutics has a one year low of $3.75 and a one year high of $7.20. The stock has a market capitalization of $8.08 million, a P/E ratio of -0.26 and a beta of 1.16. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.51.

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.50 million. Research analysts expect that Bolt Biotherapeutics will post -11.1 earnings per share for the current year.

Bolt Biotherapeutics Company Profile

(Get Free Report)

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.

See Also